2021 Infusion Therapy Standards of Practice Updates

2021 ◽  
Vol 44 (4) ◽  
pp. 189-190
2021 ◽  
Vol 44 (1S) ◽  
pp. S1-S224
Author(s):  
Lisa A. Gorski ◽  
Lynn Hadaway ◽  
Mary E. Hagle ◽  
Daphne Broadhurst ◽  
Simon Clare ◽  
...  

2019 ◽  
Vol 39 (1) ◽  
pp. 61-71 ◽  
Author(s):  
Barb Nickel

The most common invasive procedure performed in the hospital setting worldwide is the insertion of a peripheral intravenous catheter. Although use of peripheral intravenous access is common, its presence is far from benign, with a reported 35% to 50% failure rate, even in facilities with a dedicated infusion team. Significant complications related to the presence of a peripheral intravenous site include localized infection, bacteremia, phlebitis, and infiltration or extravasation. Consistent application of evidence-based standards of practice in all aspects of peripheral intravenous catheter care is essential to provide infusion therapy that delivers safe and quality care. Management of peripheral intravenous access in the complex setting of critical care is examined in this article. A case study approach is used to illustrate application of infusion therapy standards of practice in peripheral intravenous catheter insertion, indications for catheter placement, and assessment parameters to enhance early recognition of peripheral intravenous access–related complications.


2021 ◽  
pp. 112972982110150
Author(s):  
Roberto Biffi ◽  
Antonio La Greca

Early in 2021, the Infusion Nursing Society has released the latest version of the Infusion Therapy Standards of Practice. In the last two decades, these Standards have been representing one of the most important evidence-based documents available in the world of venous access. Nevertheless, we were quite concerned reading a recommendation included in chapter 26 (Vascular Access Device Planning: practice recommendation I, C): “Use a patient’s port, unless contraindicated (e.g. existing complication) as the preferred IV route in preference to insertion of an additional VAD.” Such recommendation is offered not on the basis of evidence, but as experts’ opinion (“Committee Consensus”). This Editorial deals with the opinion of GAVeCeLT (The Italian Study Group for Long Term Central Venous Access) that strongly discourage the use of ports for intravenous treatment different from chemotherapy (or from the therapy that specifically required that long term, infrequent access). The rationale for this choice is based on the consideration that the patient’s port—if used in a non-specialty ward—would be at high risk of complications, some of them potentially leading to the loss of the device, and that such complications might be particularly difficult to manage in this setting. The continuous or frequent use of a port transforms it into an external device, thus cancelling the main advantage of a totally subcutaneous location, while adding a significant disadvantage (need for repeated percutaneous punctures and risk of extravasation/infiltration due to improper insertion or dislocation of the non-coring needle). One exception is the possible use of port for radio-diagnostic purposes (as long as the port is power injectable). This strategy may be associated with advantages for the patient, and imaging quality improvement, but requires the adoption of specific protocols for prevention of infective and mechanical complications.


2017 ◽  
Vol 22 (1) ◽  
pp. 38-41 ◽  
Author(s):  
Jona V. Caparas ◽  
Hwei-San Hung

Abstract Background: The 2016 Infusion Therapy Standards of Practice no longer require that low pH (<5) medications be administered via central venous access devices. Nevertheless, the practice of placing PICCs for vancomycin administration often persists. Purpose: To demonstrate the safety and efficacy of intravenous vancomycin administration through a short and long term midline catheter. Methodology: A retrospective chart review was performed on 1086 patients who received intravenous vancomycin through a midline catheter. Results: There were no catheter-associated bloodstream infections and no deep vein thromboses. Phlebitis occurred rarely (0.6%), as did benign infiltrations (1.2%). There were no extravasation injuries. Conclusions: These outcomes summarize more than 5 years of experience administering intravenous vancomycin (4 mg/mL) safely and cost-efficiently through a nontrimmable midline catheter.


Sign in / Sign up

Export Citation Format

Share Document